Innatoss Laboratories
Private Company
Total funding raised: $5.5M
Overview
Innatoss Laboratories is a Dutch diagnostic company founded in 2014, specializing in challenging infectious diseases like Lyme, Q fever, and COVID-19. Its core strategy involves smartly utilizing or developing new immunological tests to improve diagnostic accuracy and speed, thereby aiming to prevent chronic conditions. The company engages in both commercial testing services and collaborative research with academic and patient organizations, positioning itself as a niche expert in a difficult diagnostic segment.
Technology Platform
Immunology-based diagnostic assay development and validation, including T-cell tests (Q-detect™) and surrogate virus neutralization tests (cPass™).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Innatoss competes in niche segments against large commercial labs offering standard serology and specialized university/hospital labs. For Lyme, it faces competition from companies like Zeus Scientific and Euroimmun, but differentiates with a focus on complex cases. In COVID-19 serology, it competes on quality (neutralization assays) rather than volume.